Recruiting Studies
Baxduo-PACIFIC: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific)
More information: clinicaltrials.gov
Investigational product: Baxdrostat
Population:
eGFR ≥30 and <60 mL/min/1.73 m2 with UACR between 3.39 mg/mmol and 56.5 mg/mmol, or
eGFR ≥30 and ≤75 mL/min/1.73 m2 with UACR between 56.5 mg/mmol and ≤565 mg/mmol or UPCR between 79 mg/mmol and 790 mg/mmol
Phase: III
Starting year: 2025
Participating sites: Albert Schweitzer hospital (Dordrecht), Amsterdam UMC, Isala (Zwolle), LUMC (Leiden), Meander Medisch Centrum (Amersfoort), MUMC+ (Maastricht), St. Antonius (Nieuwegein), Tergooi MC (Hilversum), UMCG (Groningen)
National lead: prof.dr. M.H. de Borst (UMCG)
PROMISE: Potassium correction for RAAS optimization in chronic kidney disease
More information: clinicaltrials.gov
Investigational product: Patiromer
Population: Stage 3b-4 CKD with ACR >3 mg/mmol
Phase: IV
Starting year: 2024
Participating sites: Amsterdam UMC, Frisius MC (Leeuwarden), Isala (Zwolle), UMCG (Groningen)
National lead: prof.dr. M.H. de Borst (UMCG)
Follow-up Studies
K+ in CKD trial
More information: clinicaltrials.gov
Investigational product: Potassium chloride / potassium citrate
Population: Stage 3b-4 CKD with ACR >3 mg/mmol
Phase: III
Starting year: 2017
National lead: prof.dr. E.J. Hoorn (Erasmus MC)
Contact NEFRO-NL
How can we help?
Would you like to know more about NEFRO-NL, our research network or our services? Our project managers will be happy to help. Contact us at info@nefro-nl.nl.
Antina de Boer
project manager
